Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (08-03). Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Sut	Substitute for form 1449A/PTO			COMPLETE IF KNOWN OF FEE SEE		
	NFORMATION I	DIS	SURE	Application Number	PCT/USO. 66 1 1 5 4 6 9	
C.	TATEMENT DV	A D	DIICANIT	Filing Date		
STATEMENT BY APPLICANT				First Named Inventor	John J. Acton III, et al	
			•	Group Art Unit		
	(use as many sheets	as n	ecessary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	21116YP	

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
NL	·	US 5,686,481		Elliott et al	11/11/1997			
DL		US 5,482,960		Berryman et al	01/09/1996			
			_					

FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document				Date of Publication of		
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document  MERCK & CO., INC.	Cited Document MM-DD-YYYY 01/31/2002		
DL		wo	2 08188					
		wo	01 30343		MERCK & CO., INC.	05/03/2001		
		wo	99/43651		GENETICS INSTITUTE, INC.	09/02/1999		
		wo	99/43672		GENETICS INSTITUTE, INC.	09/02/1999		
		wo	98/08818		GENETICS INSTITUTE, INC.	03/05/1998		
		wo	00/35886		AXYS PHARMACEUTICALS, INC.	06/22/2000		
		wo	99/43654		GENETICS INSTITUTE INC.	09/02/1999		
		EP	424 325		ONO PHARMACEUTICAL CO.LTD.	06/02/2004		
		wo	2004/006920		ELBION AG	01/22/2004		
V		wo	02/30895		BAYER CORPORATION	04/18/2002		

Examiner Signature /Deborah Lambkin/ Date Considered 11/03/2006

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



